What is William Blair’s Estimate for TMDX FY2024 Earnings?

TransMedics Group, Inc. (NASDAQ:TMDX) – Investment analysts at William Blair decreased their FY2024 EPS estimates for TransMedics Group in a report issued on Tuesday, October 29th. William Blair analyst R. Daniels now anticipates that the company will post earnings of $1.06 per share for the year, down from their previous forecast of $1.33. The consensus estimate for TransMedics Group’s current full-year earnings is $1.22 per share. William Blair also issued estimates for TransMedics Group’s Q4 2024 earnings at $0.22 EPS, Q3 2025 earnings at $0.45 EPS, Q4 2025 earnings at $0.50 EPS and FY2025 earnings at $1.74 EPS.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the prior year, the business posted ($0.12) earnings per share. The company’s revenue for the quarter was up 63.7% on a year-over-year basis.

TMDX has been the topic of a number of other research reports. Canaccord Genuity Group cut their price objective on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday. Stephens lifted their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Robert W. Baird reduced their price target on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday. Piper Sandler reissued an “overweight” rating and issued a $180.00 target price on shares of TransMedics Group in a report on Tuesday. Finally, Baird R W raised TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $144.80.

TransMedics Group Trading Up 0.1 %

NASDAQ TMDX opened at $81.97 on Thursday. The stock’s 50 day moving average is $142.38 and its 200 day moving average is $139.36. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The firm has a market capitalization of $2.73 billion, a PE ratio of 87.20 and a beta of 1.99. TransMedics Group has a twelve month low of $36.42 and a twelve month high of $177.37.

Institutional Trading of TransMedics Group

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. boosted its holdings in TransMedics Group by 260.1% in the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after buying an additional 146,115 shares during the period. Amalgamated Bank lifted its position in shares of TransMedics Group by 777.4% in the third quarter. Amalgamated Bank now owns 9,774 shares of the company’s stock valued at $1,535,000 after acquiring an additional 8,660 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of TransMedics Group by 48.2% in the third quarter. Harbor Capital Advisors Inc. now owns 8,964 shares of the company’s stock worth $1,407,000 after acquiring an additional 2,916 shares during the period. Farther Finance Advisors LLC grew its position in shares of TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares in the last quarter. Finally, New York State Teachers Retirement System bought a new stake in TransMedics Group during the 3rd quarter valued at approximately $1,217,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the transaction, the insider now directly owns 20,843 shares in the company, valued at $3,089,766.32. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock worth $9,518,181 in the last three months. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.